コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ith tryptase in estimating the need for bone marrow biopsy.
2 mastocytosis) and thus candidates for a bone marrow biopsy.
3 aggregates, and atypical mast cells on bone marrow biopsy.
4 94% and 100% for PET-CT and 40% and 100% for marrow biopsy.
5 ent accuracy to replace routine staging bone marrow biopsy.
6 e to up to 31 drugs within 5 days after bone marrow biopsy.
7 e of biopsy site than the usual random iliac marrow biopsy.
8 ne and serum immunoelectrophoresis, and bone marrow biopsy.
9 diagnosis usually depends on results of bone marrow biopsy.
10 the potential to reduce the need for staging marrow biopsy.
11 re red cell aplasia (PRCA) confirmed by bone marrow biopsy.
12 with hematologic response criteria and bone marrow biopsies.
13 ot density compared with normal control bone marrow biopsies.
14 relevance of expression in 55 archival bone marrow biopsies.
15 loid leukemia (AML) routinely undergo a bone marrow biopsy 7-10 days after induction chemotherapy to
17 Response was assessed by weekly CBC and bone marrow biopsy after cycle 2 and after each subsequent cy
19 tochemically by factor VIII staining of bone marrow biopsies and quantified by assessment of microves
20 s of blood vessels were measured in 145 bone marrow biopsies and the levels of vascular endothelial g
23 and negligible gene marking, diagnostic bone marrow biopsy and aspirate were performed at day 88.
27 ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac
28 ischemia in Tc-99m SPECT who underwent bone marrow biopsy and were allocated to cells (n=16) or plac
29 up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical and histochemical
30 is, in the selection of those needing a bone marrow biopsy, and in the documentation of disease progr
32 o identify those patients who require a bone marrow biopsy, and whether the pathogenesis of IA involv
33 suspicious lymphocytic infiltrates in a bone marrow biopsy as the sole suggestion of residual disease
35 he diagnosis of 661 PMF patients with a bone marrow biopsy at presentation was revised according to m
37 ll lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marrow inv
39 A percutaneous biopsy of the mass and bone marrow biopsy confirmed the diagnosis of primary adrenal
42 ide therapy should undergo surveillance bone marrow biopsy every 2 to 3 years and that those who show
44 icaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggregates
48 n factor (MITF), is highly expressed in bone marrow biopsies from 9 of 10 patients with systemic mast
52 taneous analysis of WM patient sera and bone marrow biopsies identified a set of dysregulated cytokin
53 tochemical paraffin section staining of bone marrow biopsies in the staging of B-cell malignant lymph
56 only used test to estimate the need for bone marrow biopsy in patients suspected to have indolent sys
57 r DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogeneity
63 se activity in the plasma isolated from bone marrow biopsies of 100 patients reveals 86 positive for
64 dominant clonotypes in blood and in historic marrow biopsies of 35 AA, 37 MDS, and 21 paroxysmal noct
65 quantify IDO-1 expression on diagnostic bone marrow biopsies of AML patients in order to facilitate i
66 cutoff correctly classifies diagnostic bone marrow biopsies of MPN,U patients specified upon follow-
69 features with the exception that their bone marrow biopsy pathology revealed abundant neutrophils co
71 Cr corresponded with the high degree of bone marrow biopsies positive for atypical mast cells, the pr
84 TMA was constructed using pretreatment bone marrow biopsy specimens from 64 adult patients with ALL.
85 e were detected on peripheral smear and bone marrow biopsy specimens, and PCR amplified Ehrlichia ewi
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。